Recent news on Erlotinib

Guidelines on skin reactions to Epidermal Growth Factor Receptor ...  -  25 May 2007
News-Medical.net,The drugs , including erlotinib (Tarceva), cetuximab (Erbitux), and panitumumab (Vectibix) , work by interfering with cell-signaling abnormalities that

A close-up on pancreatic disease: How do we improve the odds?  -  May 23, 2007
EurekAlert (press release),Epidermal growth factor receptor (or EGFR) is a major target for novel therapies such as erlotinib and ErbB3 is a specific cell receptor that is stimulated

UK Lags Behind In New Cancer Drug Uptake And Survival  -  May 11, 2007
Medical News Today,..."The greatest differences in uptake were noted for the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed."

Shedding Light on Acquired Treatment Resistance in Lung Cancer  -  Apr 26, 2007
Cancerpage.com,Gefitinib and erlotinib are used to treat non-small cell lung cancers with activating mutations in the gene for epidermal growth factor receptor.

Finding may overcome drug resistance in lung cancer  -  May 2, 2007
Cancerfacts.com,Tarceva (erlotinib) is new generation oral anti-cancer drug that targets the human epidermal growth factor receptor. Also known as EGFR, this receptor plays

Experts warn of global gulf in cancer treatment  -  May 9, 2007
ReutersThe biggest differences were seen in four new colorectal and lung cancer drugs -- Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

Targeted drug extends life in pancreatic cancer patients  -  Apr 28, 2007
Cancerfacts.com,BASEL, Switzerland – April 27, 2007 – Adding the drug erlotinib (Tarceva®) to gemcitabine chemotherapy significantly improves survival by 22 percent in

Survival in pancreatic cancer improved  -  May 7, 2007
TopCancerNews.com,The Journal of Clinical Oncology, an online publication found that adding Tarceva(erlotinib) to Gemzar(gemcitabine) can improve the chances of survival.

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 27, 2007
CNW Telbec (Communiqués de presse),About Tarceva Tarceva (erlotinib) is a small molecule that targets the human epidermal growth factor receptor (HER1) pathway. HER1, also known as EGFR,

Addition of Tarceva® to Gemzar® Improves Survival in Pancreatic Cancer  -  May 2, 2007
Cancer Consultants (press release),According to an early online publication in the Journal of Clinical Oncology, the addition of the targeted agent Tarceva® (erlotinib) to Gemzar®

Ireland Cancer Center Researchers Advance Lung Cancer Treatment  -  Apr 28, 2007
Medical News Today (press release),...cells can become resistant to novel targeted agents, such as Tarceva (erlotinib), a medication in widespread use for non-small-cell lung cancer (NSCLC).

OSI Pharmaceuticals Announces First Quarter 2007 Financial Results  -  Apr 27, 2007
PharmaLive.com (press release),The increase is primarily due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales. Total worldwide net sales of Tarceva for the

OSI Pharmaceuticals to Present at the Citigroup Global Healthcare ...  -  May 14, 2007
Business Wire (press release),OSI's flagship product, Tarceva® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

Australian scientists directly target cancer cells  -  May 11, 2007
People's Daily Online,The biggest differences were seen in four new colorectal and lung cancer drugs Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

Experts warn of global gap in cancer treatment  -  May 10, 2007
Scientific AmericanThe biggest differences were seen in four new colorectal and lung cancer drugs - bevacizumab (Avastin); cetuximab (Erbitux); erlotinib (Tarceva); (Alimta);

Report blames bureaucracy for UK cancer deaths  -  May 10, 2007
Guardian Unlimited,The lung cancer drug Tarceva (erlotinib) and the bowel cancer drug Avastin (bevacizumab) are used 10 times more in the US than in Europe.

UK 'worst on cancer drug access'  -  May 9, 2007
BBC News,For lung cancer, uptake of erlotinib was 10 times higher than the European avearge in the US and three times higher in Germany. Uptake in Australia, the UK,

‘Stark inequalities’ in access to cancer drugs  -  May 9, 2007
MSNBCThe biggest differences were seen in four new colorectal and lung cancer drugs — Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

NZ lags in access to life-saving drugs  -  May 9, 2007
TVNZ,The biggest differences were seen in four new colorectal and lung cancer drugs - Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

Britain is sick man of Europe for providing cancer drugs  -  May 9, 2007
Independent,The bowel cancer drug Avastin (bevacizumab) and the lung cancer drug Tarceva (erlotinib) are used 10 times more in the US than in Europe.

Peptech Acquiring EvoGenix In Cash, Stock Deal Worth A$156M  -  May 7, 2007
BioWorld Online,As an example that neither is necessarily better, he pointed to the EGFR cancer drugs Erbitux (cetuximab, ImClone Systems Inc.) and Tarceva (erlotinib,

AVEO Series D Pulls Down $53M For Cancer Therapies  -  May 3, 2007
BioWorld Online,Another mutation is found at exon 19, and Tarceva (erlotinib, Genentech Inc. and OSI Pharmaceuticals Inc.) has been found to have much more activity in

Treatment Strategy For Patients With Resistant Lung Tumors  -  May 2, 2007
Medical News Today (press release),Drugs like Iressa (gefitinib) and Tarceva (erlotinib) are used to treat advanced non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths in

Scientists Spot Mechanism Behind Lung Cancer Drug Resistance  -  Apr 26, 2007
Atlanta Journal Constitution (subscription),Doctors often resort to drugs such as Iressa (gefitinib) and Tarceva (erlotinib) to treat advanced non-small-cell lung cancer. These agents work by blocking

Mechanism identified for resistance to targeted lung cancer drugs  -  Apr 26, 2007
SpiritIndia,Drugs like Iressa (gefitinib) and Tarceva (erlotinib) are used to treat advanced non-small-cell lung cancer (NSCLC), the leading cause of cancer de aths in

Tarceva extends life of patients with pancreatic cancer  -  Apr 26, 2007
Pharma Times (subscription),Canada, formed the basis of the recent European approval of Tarceva (erlotinib) for the treatment of patients with metastatic pancreatic cancer (in

Tarceva extends life of patients with pancreatic cancer  -  Apr 25, 2007
Antara (press release),Basel (ANTARA News/PRNewswire-AsiaNet) - New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 25, 2007
Juraforum.de,New results published by the Journal of Clinical Oncology showthat adding Tarceva (erlotinib) to gemcitabine chemotherapysignificantly improves survival by

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  Apr 25, 2007
Earthtimes.orgNew results published by the Journal of Clinical Oncology show thatadding Tarceva (erlotinib) to gemcitabine chemotherapy significantlyimproves survival by

Tarceva(R) Extends Life of Patients with Pancreatic Cancer  -  26 Apr 2007
news aktuell (Pressemitteilung),About Tarceva Tarceva (erlotinib) is a small molecule that targets the human epidermal growth factor receptor (HER1) pathway. HER1, also known as EGFR,

Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib ...  -  Apr 18, 2007
PharmaLive.com (press release),In an oral presentation entitled "Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC)

Cyclacel Pharmaceuticals reports preclinical Seliciclib-Erlotinib ...  -  Apr 18, 2007
PipelineReview.com (press release),In two animal models of NSCLC the combination of seliciclib and erlotinib was more effective in suppressing tumor growth than either drug alone.

AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral ...  -  Apr 17, 2007
PharmaLive.com (press release),The results from the preclinical study showed that AV-412 is greater than 10 times more potent than erlotinib in genetically engineered lung tumor models

New methods for treating lung cancer cells that have become ...  -  Apr 24, 2007
News-Medical.net,...cells can become resistant to novel targeted agents, such as Tarceva (erlotinib), a medication in widespread use for non-small-cell lung cancer (NSCLC).

Spectrum Pharmaceuticals Announces Data From Three Oncology ...  -  Apr 19, 2007
PR Newswire (press release),Abstract #5434 -- Synergistic Interaction between the Oral Platinum Analog Satraplatin and Erlotinib In preclinical studies, satraplatin was active in a

Spectrum Pharmaceuticals Announces Data From Three Oncology ...  -  Apr 20, 2007
Medical News Today (press release),Erlotinib (Tarceva(R)) is a potent inhibitor of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Since upregulation of the Erk and

OSI Pharmaceuticals to Announce First Quarter and Financial ...  -  Apr 16, 2007
PharmaLive.com (press release),OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

Genentech earnings soar but Lucentis sales slow down slightly  -  Apr 12, 2007
Pharma Times (subscription),As for Genentech's other key products, US sales of the breast cancer drug Herceptin (trastuzumab) climbed just 7% to $311 million, while Tarceva (erlotinib)

ImClone shares suffer as Erbitux pancreatic cancer trial fails  -  Apr 11, 2007
Pharma Times (subscription),...all cancer deaths, or about 32000 deaths per year. If it gets approval for this indication, Erbitux would go head to head with Roche's Tarceva (erlotinib).

Patients may have to pay fortunes for cancer drugs - professor  -  Mar 30, 2007
Pharma Times (subscription),He claimed that Roche's Avastin (bevacizumab) and Tarceva (erlotinib), GlaxoSmithKline's Tykerb and ImClone's Erbitux (cetuximab) would be some of the drugs

Ascenta Therapeutics Highlights Multiple Data Presentations at ...  -  Apr 13, 2007
Genetic Engineering News (press release),Therapeutics inhibitor erlotinib (Tarceva(R)) ---------------------------------- -------------- A novel pan inhibitor of Bcl-2 and Xiongwen Mcl-1,

Genentech financially strong while Amgen struggles  -  Apr 13, 2007
BiopharmaReporter.com,Moreover, the company reported that sales of its non-small cell lung cancer Tarceva (erlotinib) grew 10 per cent to $102m, while Lucentis (ranibizumab

ImClone slides as pancreatic cancer trial misses mark  -  Apr 12, 2007
BiopharmaReporter.com,...which will assess Avastin and Gemzar with either Erbitux or another recently-launched pancreatic cancer drug, Genentech/Roche's Tarceva (erlotinib).

Gloucester Pharmaceuticals Announces Multiple Presentations of ...  -  Apr 11, 2007
PharmaLive.com (press release),Abstract #2484 "Histone deacetylase inhibitor FK228 enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" will be

Erbitux Misses In Pancreatic Cancer, Dropping ImClone  -  Apr 11, 2007
BioWorld Online,...companies developing targeted oncology agents, but there has been only one recent success: Tarceva (erlotinib, Genentech and OSI Pharmaceuticals Inc.).

Biomarkers could drive future of Roche's Tarceva in lung cancer  -  Apr 5, 2007
Pharma Times (subscription),...detection of a specific biomarker could soon identify candidates most likely to respond to targeted therapy with the Swiss firm's Tarceva (erlotinib).

Targeted Agents Appear Promising in Extending Survival in Stage IV ...  -  Mar 20, 2007
DG NewsIn second-line therapy, the guidelines suggest that erlotinib, docetaxel or permetrexed are options. If the patient continues to progress and meets criteria

UK drug cost-effectiveness body NICE rejects Roche's Tarceva  -  Mar 9, 2007
MarketWatchThe Committee was also concerned that erlotinib would not be as effective as the existing standard treatment, docetaxel.

Watchdog rejects lung cancer drug  -  Mar 9, 2007
Which?,The National Institute for Health and Clinical Excellence (Nice) issued draft guidance saying it did not believe Tarceva (erlotinib) was the best use of

Roche to appeal NICE's 'perverse' guidance on Tarceva  -  Mar 9, 2007
Pharma Times (subscription),The Switzerland-based drugs giant said that the proposed guidance by NICE not to approve Tarceva (erlotinib), launched in the UK in September 2005 to treat

Tarceva® Has Significant Activity as Initial Treatment for Elderly ...  -  Mar 9, 2007
Cancer Consultants (press release),According to results recently published in the Journal of Clinical Oncology, treatment with the single agent Tarceva® (erlotinib) is active and well

Lung cancer drug snubbed by NHS watchdog  -  Mar 9, 2007
ITV.com,Health watchdog, the National Institute for Health and Clinical Excellence (Nice) announced that it would not be recommending the drug Tarceva erlotinib for

Progression-Free Survival Called Unsteady Endpoint for Cancer Trials  -  Mar 21, 2007
MedPage Today,They cited the example of a recent phase II study evaluating erlotinib (Tarceva) and bevacizumab (Avastin) in 37 women with metastatic breast cancer.

PF-3512676 (CPG 7909) Non-Small-Cell-Lung Immuno-modulatory ...  -  Mar 16, 2007
Cancer Focus,These trials will test patients receiving PF-3512676 combined with either Avastin® (bevacizumabterm), Tarceva® (erlotinib) or Alimta® (pemetrexed).

GlaxoSmithKline: Tykerb set to boost oncology portfolio  -  Mar 15, 2007
Pharmaceutical Business Review...the pharmacologic attributes of anti-HER2 therapy Herceptin with anti-EGFR therapies such as OSI Pharmaceuticals/Genentech/Roche's Tarceva (erlotinib).

International Symposium On Targeted Anticancer Therapies (TAT2007)  -  Mar 11, 2007
Medical News Today (press release),...on Targeted Anticancer Therapies are bevacizumab, cetuximab, dasatinib, erlotinib, lapatinib, nilotinib, oblimersen sodium, sorafenib, and sunitinib.

New drugs for cancer therapy at international conference in Amsterdam  -  Mar 11, 2007
SpiritIndia,Among the drugs that will be discussed in Amsterdam over the next three days are bevacizumab, cetuximab, dasatinib, erlotinib, lapatinib, nilotinib,

Tarceva® has Significant Activity as Initial Treatment for Elderly ...  -  Mar 8, 2007
Cancer Consultants (press release),Researchers from the Dana-Farber Cancer Center have reported that Tarceva (erlotinib) is active and well tolerated as first-line therapy for patients 70

OSI Pharmaceuticals to Present at the Cowen & Company Healthcare ...  -  Mar 8, 2007
Business Wire (press release),OSI's flagship product, Tarceva® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

Global Market for Cancer Immunotherapy Worth $37.2 Billion by 2012  -  Mar 7, 2007
PharmaLive.com (press release),...to be joined in the blockbuster category by the monoclonal antibody product Avastin (bevacizumab) and the tyrosine kinase inhibitor Tarceva (erlotinib).

Medical Management of Patients With Head and Neck Cancer  -  Mar 1, 2007
Medscape (subscription)The EGFR inhibitor erlotinib is approved for the treatment of non-small-cell lung cancer and pancreatic cancer, but its use in HNC remains undetermined.

AstraZeneca starts new Zactima lung cancer trial  -  Feb 27, 2007
Pharma Times (subscription),...is AstraZeneca's fourth Phase III trial in this tumour and two of the others are looking at Zactima in combination with docetaxel and versus erlotinib.

Fourth Fase III study of vandetanib in lung cancer patients  -  Feb 27, 2007
Antara (press release),Study 57 - a randomised, double-blind, study of vandetanib 300mg monotherapy versus erlotinib 150mg in patients with advanced NSCLC after failure of at

New Blood Cancer Therapies Under Study  -  Feb 6, 2007
Journal of American Medical Association (subscription),This was the goal of a team of researchers in France who set out to test the drug erlotinib for the treatment of myelodysplastic syndrome and acute myeloid

Clinical Trials Update: Feb. 20, 2007  -  Feb 20, 2007
Atlanta Journal Constitution (subscription),Patients will receive either Zactima or Erlotinib, and treatment will continue for 16 weeks or longer if the lung cancer does not worsen.

OSI Pharmaceuticals Announces Year End 2006 Financial Results  -  Feb 23, 2007
Oxfordshire Bioscience Network (press release),The increase was primarily due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales, and the addition of Macugen(R) (pegaptanib

Tarceva: European Approval for Pancreatic Cancer Treatment ...  -  Jan 29, 2007
DG NewsBASEL, SWITZERLAND -- January 29, 2007 -- Roche's innovative cancer drug Tarceva (erlotinib) has been approved today by the European Commission for the

New drugs in the battle against cancer  -  Feb 4, 2007
ic Wales,Why is it better: The manufacturers claim erlotinib is at least equivalent to docetaxel (another lung cancer drug) in terms of overall survival and that

OSI Pharmaceuticals Announces Year End 2006 Financial Results  -  Feb 21, 2007
Business Wire (press release),The increase was primarily due to the growth in revenues arising from worldwide Tarceva® (erlotinib) sales, and the addition of Macugen® (pegaptanib sodium

Europe backs Roche's Tarceva for pancreatic cancer  -  Jan 30, 2007
Pharma Times (subscription),The green light for Tarceva (erlotinib), which was approved in the USA for this indication in November, was based on data from a Phase III which show that

Tarceva : European Approval For Pancreatic Cancer Treatment  -  Feb 5, 2007
Medical News Today (press release),Roche's innovative cancer drug Tarceva (erlotinib), has been approved today by the European Commission for the treatment of patients with metastatic

Infinity and MedImmune Initiate Phase I/II Clinical Trial of IPI ...  -  Feb 15, 2007
PipelineReview.com (press release),..."Targeted therapies such as erlotinib and gefitinib have improved outcomes in many lung cancer patients, but resistance to these agents remains a challenge.

OSI Pharmaceuticals Announces European Regulatory Approval of ...  -  Jan 29, 2007
PharmaLive.com (press release),OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

Genentech Announces Additional Effort to Support Patient Access ...  -  Feb 16, 2007
Financial News USA (press release),Foundation (GATCF), to help address the needs of financially eligible Medicare beneficiaries enrolled in Part D who are prescribed Tarceva® (erlotinib).

Genta Incorporated Announces Fourth Quarter and Year End 2006 ...  -  Feb 15, 2007
Drug Newswire (press release),Discontinuous (twice per week) intravenous (IV) treatment with Genasense increased the activity of multiple tyrosine kinase inhibitors, including erlotinib,

Modeling Lung Cancer: New Mouse Model Validates Targeted ...  -  Feb 13, 2007
Science Daily (press release)Chicago area hospital currently enrolling participants in a research study to find out if the drug Tarceva, also know as erlotinib, may help fight .

OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2006 ...  -  Feb 9, 2007
Business Wire (press release),OSI's flagship product, Tarceva ® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have

ImClone Opts Out Of UCB Deal To Develop CDP-791  -  Feb 6, 2007
BioWorld Online,Other EGFR-targeting cancer drugs include Tarceva (erlotinib, Genentech Inc. and OSI Pharmaceuticals Inc.) and Iressa (gefitinib, AstraZeneca plc),

Funding can depend on where you live  -  Feb 5, 2007
ic Wales,The spokesperson added, “Currently the LHB has been asked to fund a number of patients for the drug Erlotinib (corr) for lung cancer, to date no funding has

Pertuzumab Ineffective in Prostate Cancer  -  Feb 5, 2007
Medscape (subscription)..."Though the activity of pertuzumab, trastuzumab, and erlotinib in ovarian, breast, and lung cancer suggests that target inhibition was likely achieved with

OSI Pharmaceuticals Announces European Regulatory Approval of ...  -  Feb 2, 2007
Oxfordshire Bioscience Network (press release),29, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche, its international partner for Tarceva(R) (erlotinib), announced today that the European

Exelixis Appoints Jose Baselga, MD, a Leading Expert in Oncology ...  -  Jan 30, 2007
Drug Newswire (press release),...contributions to the clinical development of several approved targeted cancer therapies, including trastuzumab, cetuximab, gefitinib and erlotinib.

Octreotide of No Benefit in Advanced Liver Cancer  -  Jan 26, 2007
Cancerpage.com,...erlotinib, sorafenib and others) or monoclonal antibodies against vascular endothelial growth factor or epidermal growth factor receptor (bevacizumab,

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),Two years since its launch in 2004, sales and usage of Tarceva (erlotinib), a targeted drug with proven survival benefit in advanced non-small cell lung

Microsatellite Instability, EGFR Testing, and FISH  -  Feb 2, 2007
Medscape (subscription)Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144. Abstract. Hirsch FR, Varella-Garcia M, Bunn PA,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional